Tenon Medical registered up to 1,836,046 common shares for resale by selling stockholders, while the company will receive no proceeds from those sales. Investors should distinguish that resale from cash Warrant exercises, whose proceeds Tenon intends for Working Capital and general corporate purposes.
Key Highlights
- Tenon Medical lists 2,768,975 common shares outstanding after the offering, assuming all warrants are exercised and milestone shares are issued.
- Selling holders may conduct transactions privately or publicly at prevailing, related or negotiated prices.
- Tenon Medical will not receive proceeds from shares sold by selling stockholders.
Tenon Medical, Inc. (NASDAQ: TNON) registered up to 1,836,046 common shares for resale by selling stockholders. The selling stockholders will receive the proceeds from any shares sold under the prospectus, while Tenon Medical will receive none from those transactions.
Shares Registered for Resale
The registered shares include up to 597,610 shares issuable through pre-funded warrants dated August 31, 2026. Another 1,058,517 shares could be issued through Series A common stock purchase warrants dated August 31, 2026. The pool also contains 63,380 shares issued to accredited investors in a private Placement and up to 63,380 shares issuable through related common stock purchase warrants. The private placement took place on November 14, 2025, under purchase agreements dated November 10, 2025. Employment agreement shares account for 3,947 shares issued to Wyatt Geist and 3,947 shares issued to Nathaniel Grawey, with both amounts subject in part to vesting schedules. The registration also covers 28,187 SV Shares and 16,890 SV Milestone Shares. The shares are being offered by selling stockholders rather than Tenon Medical.
Selling Holders Set Terms
Selling stockholders, or their successors, may sell the shares through public or private transactions. Permitted prices include prevailing market prices, prices linked to prevailing market prices and privately negotiated prices. Resales may also involve underwriters, broker-dealers or agents, which may receive discounts, concessions or commissions. The selling stockholders may choose to sell some, all or none of the shares. Tenon Medical will not receive proceeds from those resale transactions. The selling stockholders will receive the sale proceeds.
Use of Proceeds
Tenon Medical said proceeds from cash exercises of the warrants are intended for working capital and general corporate purposes.
Post-Offering Share Count
That calculation starts with 1,032,578 common shares outstanding as of August 31, 2026. The calculation excludes 2,210,739 shares issuable upon exercise of outstanding warrants, which have a weighted average exercise price of $9.24 per share. The prospectus identifies Armistice Capital Master Fund Ltd. with 1,867,891 shares owned before the offering and 1,656,127 shares offered for resale. The table shows 211,764 shares owned after the offering and 7.65% beneficial ownership after the offering under its stated assumptions.





Please wait processing your request...